Insulin resistance in lean and overweight nondiabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI

PLoS ONE

Volumn 13, Issue 2, 2018, Pages

  Gonzalez Cantero, Jorge ^a,b   Martin Rodriguez, Jose Luis ^c   Gonzalez Cantero, Alvaro ^c,d   Arrebola, Juan Pedro ^d,e   Gonzalez Calvin, Jorge Luis ^b,c,e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CAUCASIAN; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NORMAL HUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RISK FACTOR; WAIST CIRCUMFERENCE; CASE CONTROL STUDY; LIVER; METABOLISM; MIDDLE AGED;

ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 85041906594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0192663     Document Type: Article

References (37)

1. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015; 61: 153–160. https://doi.org/10.1002/hep.27395 PMID: 25145475
2. Leite NC, Salles GF, Araujo ALE, Villela-Nogueira CA, Cardoso CRL. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29: 113–9. https://doi.org/10.1111/j.1478-3231.2008.01718.x PMID: 18384521
3. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274–285. https://doi.org/10.1111/j.1365-2036.2011.04724.x PMID: 21623852
4. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363: 1341–50. https://doi.org/10.1056/NEJMra0912063 PMID: 20879883
5. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017; 66: 1138–1153. https://doi.org/10.1136/gutjnl-2017-313884 PMID: 28314735
6. Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology. 2005; 129: 113–121. https://doi.org/10.1053/j.gastro.2005.04.014 PMID: 16012941
7. Rafiq N, Bai C, Fang YUN, Srishord M, Mccullough A, Gramlich T, et al. Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver. YJCGH. AGA Institute; 2009; 7: 234–238. https://doi.org/10.1016/j.cgh.2008.11.005 PMID: 19049831
8. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005; 288: E462–E468. https://doi.org/10.1152/ajpendo.00064.2004 PMID: 15339742
9. Reeder SB. Quantitative Assessment of Liver Fat with Magnetic Resonance. J Magn Reson Imaging. 2012; 34: 1–38.
10. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le T-A, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58: 1930–40. https://doi.org/10.1002/hep.26455 PMID: 23696515
11. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and Intraobserver Variability in the Sonographic Assessment of Fatty Liver. Am J Roentgenol. 2007; 189: W320–W323. https://doi.org/10.2214/AJR.07.2123 PMID: 18029843
12. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009; 51: 1061–7. https://doi.org/10.1016/j.jhep.2009.09.001 PMID: 19846234
13. Martín-Rodríguez JL, Arrebola JP, Jiménez-Moleón JJ, Olea N, González-Calvin JL. Sonographic quantification of a Hepato-Renal Index for the assessment of hepatic steatosis in comparison with 3T proton magnetic resonance spectroscopy. Eur J Gastroenterol Hepatol. 2014; 26: 88–94. https://doi.org/10.1097/MEG.0b013e3283650650 PMID: 23921844
14. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012; 91: 319–27. https://doi.org/10.1097/MD.0b013e3182779d49 PMID: 23117851
15. Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014; 34: 604–611. https://doi.org/10.1111/liv.12454 PMID: 24382309
16. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004; 164: 2169–75. https://doi.org/10.1001/archinte.164.19.2169 PMID: 15505132
17. Liu C-J. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012; 27: 1555–60. https://doi.org/10.1111/j.1440-1746.2012.07222.xPMID: 22741595
18. Wei JL, Leung JC-F, Loong TC-W, Wong GL-H, Yeung DK-W, Chan RS-M, et al. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am J Gastroenterol. 2015; 110: 1306–14; quiz 1315. https://doi.org/10.1038/ajg.2015.235 PMID: 26215532
19. 2. J Clin Endocrinol Metab. 2016; 101: 3676–3684. https://doi.org/10.1210/jc.2016-1650 PMID: 27383116
20. Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol. 2017; 112: 102–110. https://doi.org/10.1038/ajg.2016.318 PMID: 27527746
21. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004; 40: 1387–1395. https://doi.org/10.1002/hep.20466 PMID: 15565570
22. Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017; 96: e6770. https://doi.org/10.1097/MD.0000000000006770 PMID: 28445310
23. Onat A, Avcı GŞ, Barlan MM, Uyarel H, Uzunlar B, Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes. 2004; 28: 1018–1025. https://doi.org/10.1038/sj.ijo.0802695 PMID: 15197408
24. Kullberg J, von Below C, Lönn L, Lind L, Ahlström H, Johansson L. Practical approach for estimation of subcutaneous and visceral adipose tissue. Clin Physiol Funct Imaging. 2007; 27: 148–153. https://doi.org/10.1111/j.1475-097X.2007.00728.x PMID: 17445065
25. Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci. 2017; 131: 2701–2704. https://doi.org/10.1042/CS20170987 PMID: 29109303
26. Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L. Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr. 1988; 48: 1351–61. PMID: 3202084
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412–9. PMID: 3899825
28. Cuthbertson DJ, Steele T, Wilding JP, Halford JC, Harrold JA, Hamer M, et al. What have human experimental overfeeding studies taught us about adipose tissue expansion and susceptibility to obesity and metabolic complications? Int J Obes. 2017; 41: 853–865. https://doi.org/10.1038/ijo.2017.4 PMID: 28077863
29. Knudsen SH, Hansen LS, Pedersen M, Dejgaard T, Hansen J, Hall G Van, et al. Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men. J Appl Physiol. 2012; 113: 7–15. https://doi.org/10.1152/japplphysiol.00189. 2011 PMID: 22556394
30. McLaughlin T, Lamendola C, Liu A, Abbasi F. Preferential Fat Deposition in Subcutaneous Versus Visceral Depots Is Associated with Insulin Sensitivity. J Clin Endocrinol Metab. 2011; 96: E1756–E1760. https://doi.org/10.1210/jc.2011-0615 PMID: 21865361
31. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol. 2010; 25: 352–356. https://doi.org/10.1111/j.1440-1746.2009.05998.x PMID: 19817963
32. Oka R, Yagi K, Sakurai M, Nakamura K, Nagasawa S, Miyamoto S, et al. Impact of visceral adipose tissue and subcutaneous adipose tissue on insulin resistance in middle-aged Japanese. J Atheroscler Thromb. 2012; 19: 814–22. PMID: 22813532
33. Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004; 30: 569–72. PMID: 15671927
34. Omelchenko E, Gavish D, Shargorodsky M. Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens. Elsevier Ltd; 2014; 8: 376–80. https://doi.org/10.1016/j.jash.2014.03.002 PMID: 24794207
35. Gonzalez-Calvin JL, Gallego-Rojo F, Fernandez-Perez R, Casado-Caballero F, Ruiz-Escolano E, Oli-vares EG. Osteoporosis, mineral metabolism, and serum soluble tumor necrosis factor receptor p55 in viral cirrhosis. J Clin Endocrinol Metab. 2004; 89: 4325–30. https://doi.org/10.1210/jc.2004-0077 PMID: 15356028
36. González-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibañez JJ. Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis. J Clin Endocrinol Metab. 2009; 94: 4844–4850. https://doi.org/10.1210/jc.2009-0835 PMID: 19897681
37. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-α or adiponectin? Hepatology. 2004; 40: 46–54. https://doi.org/10.1002/hep.20280 PMID: 15239085